BURNABY, BC, Jan. 25 /CNW/ - Welichem Biotech Inc. (the "Company")
(TSX-V: WBI), announced today that the Company filed its second quarter
financials and MD&A. The net loss for the three month period ended November
30, 2007 was $493,483 (2006 - $831,878) or 1 cent per share (2006 - 2 cents
per share). The net loss for the six month period ended November 30, 2007 was
$1,086,587 (2006 - $1,698,579) or 2 cent per share (2006 - 3 cents per share).
Detailed information is available on SEDAR website (www.sedar.com).
About Welichem Biotech Inc.
Welichem Biotech Inc. is a publicly-traded biotechnology company
developing therapeutic drugs in the fields of autoimmune diseases and cancer.
ON BEHALF OF THE BOARD
York Yingping Guo
President & Chief Executive Officer
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of the content of this news
release. This press release contains forward-looking statements that include
our belief as to the potential of our products. Certain risks and
uncertainties such as our ability to successfully commercialize the products
could cause the Company's actual results to differ materially from those in
the forward-looking statements.
For further information:
For further information: York Yingping Guo, Tel.: (604) 432-1703, Email: